Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02090933 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02090933 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants.
The verdict
NCT02090933, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This clinical trial studies celecoxib in decreasing the damaging effects of sunburn in healthy volunteers. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Celecoxib
- PROCEDURE UV Light Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-03 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02090933
The ClinicalTrials.gov registry entry for NCT02090933 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02090933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02090933 about?
NCT02090933 is a clinical study titled "Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers". This clinical trial studies celecoxib in decreasing the damaging effects of sunburn in healthy volunteers. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers.
What is the current status of trial NCT02090933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-03. Estimated completion is 2004-12.
What interventions are being tested in trial NCT02090933?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Celecoxib (DRUG), UV Light Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT02090933?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.